Atlas Venture Fund XI, L.P.'s Form 4 filing
Dyne Therapeutics, Inc. (DYN) · filed Dec 14, 2022
- Accession no.
- 0001209191-22-061243
- Filed
- Dec 14, 2022, 4:55 PM ET
- Trade date
- Dec 12, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $10.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Atlas Venture Fund XI, L.P.CIK 0001708269 | 10% Owner |
| Atlas Venture Opportunity Fund I, L.P.CIK 0001759241 | 10% Owner |
| Atlas Venture Associates Opportunity I, L.P.CIK 0001780065 | 10% Owner |
| Atlas Venture Associates Opportunity I, LLCCIK 0001780066 | 10% Owner |
| Atlas Venture Associates XI, LLCCIK 0001780067 | 10% Owner |
| Atlas Venture Associates XI, L.P.CIK 0001780068 | 10% Owner |
| Atlas Venture Opportunity Fund II, L.P.CIK 0001885327 | 10% Owner |
| Atlas Venture Associates Opportunity II, LLCCIK 0001935810 | 10% Owner |
| Atlas Venture Associates Opportunity II, LPCIK 0001935814 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 12, 2022 | Common Stock | PPurchaseAcquired | +934,581 | $10.70 | +$10,000,016.7 | 934,581 | Direct | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.